Appeal No. 95-3117
Application 08/096,207
Poisoning,” Fundam. Appl. Toxicol., Vol. 5, pp. S182-S203
(1985). Claims 23 and 28 are representative of the subject
matter claimed and read:
23. A compound for the selective inhibition of
acetylcholinesterase selected from the group consisting
of:
(-)-2'-methylphenylcarbamoyleseroline (1),
(-)-2'-methylphenylcarbamoyl-N1-noreseroline (11),
(-)-phenylcarbamoyl-N1-noreseroline (14),
and pharmaceutically acceptable salts thereof.
28. A method for inhibiting acetylcholinesterase
activity comprising administering an effective amount of
at least one compound according to claim 23 to a mammal
in need thereof.
Discussion
We have considered the entire record, including the
claims on appeal; the supporting specification; the Appeal
Brief; the Examiner’s Answer; the Reply Brief; the teachings
of Yu I, Glamkowski, Yu II, and Albuquerque; and the
Declarations of
Dr. Arnold Brossi, signed May 19, 1994, and Dr. Nigel H.
Greig, signed June 23, 1993. We have also considered
Brzostowska
et al. (Brzostowska), “Phenylcarbamates of (-)-Eseroline,
(-)-N -Noreseroline and (-)-Physovenol: Selective Inhibitors1
of Acetyl and, or Butyrylcholinesterase,” Med. Chem. Res.,
- 3 -
Page: Previous 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 Next
Last modified: November 3, 2007